SAN FRANCISCO, Nov. 10, 2021 /PRNewswire/ -- GI Partners, a
leading private investment firm, today announced the signing of a
definitive agreement to sell Generate Life Sciences ("Generate"), a
leading life sciences platform that provides reproductive and
newborn stem cell (umbilical cord blood and tissue) services, to
CooperCompanies (NYSE:COO).
Generate Life Sciences was created by GI Partners in 2018 as the
combination of California Cryobank Life Sciences, an
industry-leading donor sperm and egg bank, and Cord Blood Registry,
a leading provider of newborn stem cell services. The combined
business became a key player in three highly complementary
end-markets. Generate serves families from preconception to
post-birth throughout the significant and highly personalized
journey of building a family and protecting their children's
health. Built upon the pillars of innovation, access, and
connection, Generate has helped grow and protect nearly one million
families globally.
Dave Kreter, Managing Director at
GI Partners, said, "With the combination of these two leading
companies we had a vision to create and build a platform that could
address the personal desires of families' reproductive and stem
cell needs. Over the past three years we have focused our efforts
and expertise to further Generate's leadership and expand its suite
of offerings. We would like to thank CEO Richard Jennings and his team for their
partnership to build a leading life sciences company that serves
customers in over 30 countries today."
Richard Jennings, Chief Executive
Officer of Generate, added, "Generate helps families around the
world benefit from an industry leading suite of reproductive, stem
cell, and genetic services. Over the past several years, our
company has transformed into a global organization supporting
clients who want to create and protect healthy families. GI
Partners has been instrumental in accelerating our growth in new
markets and providing greater access to innovative science that
promotes family wellness."
The transaction is subject to customary closing conditions and
is expected to be completed in December.
About Generate Life Sciences
Generate Life Sciences
Inc. is a life sciences company helping to grow and protect
families through reproductive, newborn stem cell, genetic
screening, medical device, and healthcare technology services. We
serve families from preconception to post-birth. Our brands
— CBR® (Cord Blood Registry®), California
Cryobank®, Donor Egg Bank USA™, NW
Cryobank®, ReadyGen®, Kitazato USA®, and Donor Application™ — are
pioneering leaders that have helped nearly one million families.
Headquartered in Los Angeles,
Generate operates facilities in Tucson, New
York, Boston, Palo Alto, and Rockville, MD. Generate is a portfolio company
of GI Partners, a private investment firm based in San Francisco. For more information, visit
www.generate.com.
About GI Partners
Founded in 2001, GI Partners is a private investment firm with over
100 employees and offices in San
Francisco, New York,
Chicago, Greenwich, and
Scottsdale. The firm has raised over $29
billion in capital from leading institutional investors
around the world to invest in private equity, real estate, and data
infrastructure strategies. The private equity team invests
primarily in companies in the healthcare, IT infrastructure,
services, and software sectors. The real estate team focuses
primarily on technology and life sciences properties as well as
other specialized types of real estate. The data infrastructure
team invests primarily in hard asset infrastructure businesses
underpinning the digital economy. For more information, please
visit www.gipartners.com.
Media Contacts:
Chris Tofalli
Chris Tofalli Public Relations, LLC
914-834-4334
Gretchen Robinson
GI Partners
GRobinson@gipartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gi-partners-announces-agreement-to-sell-generate-life-sciences-to-coopercompanies-301421584.html
SOURCE GI Partners